San Francisco, CA–(Newsfile Corp. – December 25, 2024) – On December 9, 2024, simply months after finishing an IPO in September 2024, BioAge Labs, Inc. (NASDAQ: BIOA) has surprisingly introduced that it’s ending a part 2 research of its flagship product, azelaprag, meant to deal with metabolic ailments corresponding to weight problems.
Hagens Berman has opened an investigation and is urging BioAge buyers who bought shares through the firm’s IPO or on the open market and suffered substantial losses to submit their losses now.
Go to: www.hbsslaw.com/investor-fraud/bioa
Contact the agency now: BIOA@hbsslaw.com
844-916-0895
BioAge Labs, Inc. (BIOA) Survey:
The investigation focuses on the accuracy of BioAge’s disclosures concerning security information and different issues associated to azelaprag, which the corporate mentioned in its IPO filings was “nicely tolerated in 265 folks throughout eight part 1 scientific trials.”
BioAge’s disclosures have been known as into query after the market closed on December 6, 2024, when the corporate introduced the discontinuation of the Section 2 STRIDES scientific trial evaluating azelaprag together with tirzepatide for the remedy of l ‘weight problems. BioAge acknowledged that hepatic transaminitis has been noticed in sufferers receiving azelaprag.
This information induced BioAge’s inventory value to fall by nearly 80% on December 9, 2024.
“We’re centered on whether or not BioAge was clear to buyers concerning the security profile of azelaprag earlier than the Dec. 6 announcement,” mentioned Reed Kathrein, the Hagens Berman companion who runs the investigation.
In case you invested in BioAge and suffered substantial losses, or have data that might help the corporate’s investigation, submit your losses now »
If you need extra info and solutions to often requested questions in regards to the BioAge survey, learn on »
Whistleblowers: People with personal info concerning BioAge ought to take into account their choices for aiding within the investigation or profiting from the SEC’s whistleblower program. Below the brand new program, whistleblowers who present unique info can obtain rewards totaling as much as 30% of any profitable restoration made by the SEC. For extra info, name Reed Kathrein at 844-916-0895 or e mail BIOA@hbsslaw.com.
# # #
About Hagens Berman
Hagens Berman is a worldwide complicated plaintiffs’ rights litigation agency centered on company legal responsibility. The agency has a robust follow and represents buyers in addition to whistleblowers, staff, customers and others in circumstances that obtain actual outcomes for folks harmed by company and different negligence wrongdoing. The Hagens Berman workforce has secured over $2.9 billion on this space of regulation. To study extra in regards to the firm and its successes, go to hbsslaw.com. Observe the agency for updates and information at @ClassActionLaw.
To view the supply model of this press launch, please go to https://www.newsfilecorp.com/launch/235182
#BioAge #Labs #BIOA #Azelaprag #Lawsuit #Ruling #Raises #Questions #PreIPO #Disclosures , #Gossip247
,
